111 results
6-K
EX-99.1
GLPG
Galapagos NV
16 May 24
Current report (foreign)
8:11am
with Blood Centers of America, including the benefits of such collaboration, and statements regarding Galapagos’ CAR-T manufacturing platform. Forward … the potential benefits of such collaboration, may be incorrect, the inherent uncertainties associated with competitive developments and regulatory
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
related to the acquisitions of CellPoint and AboundBio, including the risk that we may not achieve the anticipated benefits of the acquisitions of CellPoint … the anticipated benefits of such exercise on the currently envisaged timeline or at all. A further list and description of these risks, uncertainties and other
6-K
GLPG
Galapagos NV
1 May 24
Current report (foreign)
5:10pm
: Each new share to be issued by the Company upon each exercise of the Warrant shall be fully paid up and shall have the same rights and benefits
6-K
EX-99.5
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
and direct social benefits
Employers’ contribution for social security
Employers’ premiums for extra statutory insurance
Other personnel costs
Retirement … OF TRANSACTIONS NOT REFLECTED IN THE BALANCE SHEET
If the risks and benefits resulting from such transactions are of any meaning and if publishing such risks
6-K
EX-99.14
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
by the Company upon each exercise of the Warrant shall be fully paid up and shall have the same rights and benefits as, and rank pari passu in all respects
6-K
EX-99.3
07nqjlgvi6 4p5m
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.4
mzivnrbiix2 5nl
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.7
l94mz4h5tobstgj72g
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.2
85s4levazprju49w785e
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.15
nn2fdct
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
7gz6 yxmyj
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
6-K
EX-99.1
3on 58e0c
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
uy4o8ivom5vxfa dt4u
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
1rv9qz5nnyqxk
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
j199ltpyox209o6xfyg
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm